-+ 0.00%
-+ 0.00%
-+ 0.00%

LARIMAR THERAPEUTICS - NOMLABOFUSP LONG-TERM DOSING GENERALLY WELL-TOLERATED; ANAPHYLAXIS IN 10 OF 43 PATIENTS

Reuters·06/29/2026 10:30:00

Please log in to view news